A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.
electrochemotherapy
histopathological findings
imaging findings
irreversible electroporation
radiofrequency ablation
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
23
04
2021
revised:
16
05
2021
accepted:
19
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
2
7
2021
Statut:
epublish
Résumé
Imaging methods and the most appropriate criteria to be used for detecting and evaluating response to oncological treatments depend on the pathology and anatomical site to be treated and on the treatment to be performed. This document provides a general overview of the main imaging and histopathological findings of electroporation-based treatments (Electrochemotherapy-ECT and Irreversible electroporation-IRE) compared to thermal approach, such as radiofrequency ablation (RFA), in deep-seated cancers with a particular attention to pancreatic and liver cancer. Numerous electronic datasets were examined: PubMed, Scopus, Web of Science and Google Scholar. The research covered the years from January 1990 to April 2021. All titles and abstracts were analyzed. The inclusion criteria were the following: studies that report imaging or histopathological findings after ablative thermal and not thermal loco-regional treatments (ECT, IRE, RFA) in deep-seated cancers including pancreatic and liver cancer and articles published in the English language. Exclusion criteria were unavailability of full text and congress abstracts or posters and different topic respect to inclusion criteria. 558 potentially relevant references through electronic searches were identified. A total of 38 articles met the inclusion criteria: 20 studies report imaging findings after RFA or ECT or IRE in pancreatic and liver cancer; 17 studies report histopathological findings after RFA or ECT or IRE; 1 study reports both imaging and histopathological findings after RFA or ECT or IRE. Imaging features are related to the type of therapy administrated, to the timing of re-assessment post therapy and to the imaging technique being used to observe the effects. Histological findings after both ECT and IRE show that the treated area becomes necrotic and encapsulated in fibrous tissue, suggesting that the size of the treated lesion cannot be measured as an endpoint to detect response. Moreover, histology frequently reported signs of apoptosis and reduced vital tissue, implying that imaging criteria, which take into account the viability and not the size of the lesion, are more appropriate to evaluate response to treatment.
Sections du résumé
BACKGROUND
Imaging methods and the most appropriate criteria to be used for detecting and evaluating response to oncological treatments depend on the pathology and anatomical site to be treated and on the treatment to be performed. This document provides a general overview of the main imaging and histopathological findings of electroporation-based treatments (Electrochemotherapy-ECT and Irreversible electroporation-IRE) compared to thermal approach, such as radiofrequency ablation (RFA), in deep-seated cancers with a particular attention to pancreatic and liver cancer.
METHODS
Numerous electronic datasets were examined: PubMed, Scopus, Web of Science and Google Scholar. The research covered the years from January 1990 to April 2021. All titles and abstracts were analyzed. The inclusion criteria were the following: studies that report imaging or histopathological findings after ablative thermal and not thermal loco-regional treatments (ECT, IRE, RFA) in deep-seated cancers including pancreatic and liver cancer and articles published in the English language. Exclusion criteria were unavailability of full text and congress abstracts or posters and different topic respect to inclusion criteria.
RESULTS
558 potentially relevant references through electronic searches were identified. A total of 38 articles met the inclusion criteria: 20 studies report imaging findings after RFA or ECT or IRE in pancreatic and liver cancer; 17 studies report histopathological findings after RFA or ECT or IRE; 1 study reports both imaging and histopathological findings after RFA or ECT or IRE.
CONCLUSIONS
Imaging features are related to the type of therapy administrated, to the timing of re-assessment post therapy and to the imaging technique being used to observe the effects. Histological findings after both ECT and IRE show that the treated area becomes necrotic and encapsulated in fibrous tissue, suggesting that the size of the treated lesion cannot be measured as an endpoint to detect response. Moreover, histology frequently reported signs of apoptosis and reduced vital tissue, implying that imaging criteria, which take into account the viability and not the size of the lesion, are more appropriate to evaluate response to treatment.
Identifiants
pubmed: 34073865
pii: ijerph18115592
doi: 10.3390/ijerph18115592
pmc: PMC8197272
pii:
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Radiol Med. 2021 Mar;126(3):437-444
pubmed: 33025303
J Nucl Med. 2018 Apr;59(4):551-556
pubmed: 29348320
Acta Oncol. 2015 Mar;54(3):289-97
pubmed: 25591820
Radiol Oncol. 2018 Oct 18;52(4):383-391
pubmed: 30352044
Jpn J Radiol. 2015 Jul;33(7):424-32
pubmed: 26032929
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
pubmed: 2462423
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Surg. 2015 Jun;18:230-6
pubmed: 25917204
Pancreas. 2014 Aug;43(6):938-45
pubmed: 24717825
Clin Transplant. 2006 Nov-Dec;20(6):695-705
pubmed: 17100718
Radiology. 2016 Jan;278(1):285-94
pubmed: 26523493
Clin Cosmet Investig Dermatol. 2016 Nov 23;9:451-459
pubmed: 27920565
Acta Radiol. 2015 Feb;56(2):133-42
pubmed: 24523360
Nanomedicine (Lond). 2014;9(8):1181-92
pubmed: 24024571
AJR Am J Roentgenol. 2015 May;204(5):1000-7
pubmed: 25905934
Eur J Surg Oncol. 2018 May;44(5):651-657
pubmed: 29402556
Sci Rep. 2019 Mar 12;9(1):4285
pubmed: 30862897
Radiology. 2012 Jan;262(1):117-25
pubmed: 22106355
AJR Am J Roentgenol. 2017 May;208(5):1141-1146
pubmed: 28177652
Radiol Med. 2019 May;124(5):331-338
pubmed: 30560501
AJR Am J Roentgenol. 2006 Jun;186(6):1783-6
pubmed: 16714674
Radiol Med. 2014 Jul;119(7):449-50
pubmed: 25001586
J Magn Reson Imaging. 2010 Jul;32(1):2-16
pubmed: 20575076
Eur Radiol. 2017 Jun;27(6):2521-2531
pubmed: 27659702
World J Gastroenterol. 2013 Feb 14;19(6):855-65
pubmed: 23430451
Int J Mol Med. 2003 Feb;11(2):199-204
pubmed: 12525878
Therap Adv Gastroenterol. 2020 May 21;13:1756284819885052
pubmed: 32499833
Curr Probl Diagn Radiol. 2009 May-Jun;38(3):135-43
pubmed: 19298912
Anticancer Drugs. 2000 Mar;11(3):201-8
pubmed: 10831279
Radiol Med. 2020 Dec;125(12):1233-1242
pubmed: 32424659
Gastrointest Endosc. 2016 Feb;83(2):440-3
pubmed: 26344883
Ann Surg Oncol. 2020 Dec;27(Suppl 3):954-955
pubmed: 33011913
J Clin Med. 2021 Mar 22;10(6):
pubmed: 33810058
J Healthc Eng. 2019 Jan 3;2019:2784516
pubmed: 30719264
Radiology. 2010 Aug;256(2):424-32
pubmed: 20656834
Radiol Med. 2019 Oct;124(10):1043-1048
pubmed: 31270723
Eur J Surg Oncol. 2016 Dec;42(12):1914-1923
pubmed: 27424789
Radiol Med. 2013 Feb;118(1):140-51
pubmed: 22430675
World J Gastroenterol. 2010 Oct 28;16(40):5104-10
pubmed: 20976848
Anticancer Res. 2001 Jul-Aug;21(4A):2483-8
pubmed: 11724311
IEEE Trans Biomed Eng. 2006 Jul;53(7):1409-15
pubmed: 16830945
AJR Am J Roentgenol. 2013 Jan;200(1):184-93
pubmed: 23255761
J Vasc Interv Radiol. 2008 Jul;19(7):1087-92
pubmed: 18589324
Radiol Oncol. 2019 Oct 10;53(4):415-426
pubmed: 31600140
Technol Cancer Res Treat. 2016 Dec;15(6):737-748
pubmed: 26351303
Radiol Med. 2020 Jul;125(7):668-673
pubmed: 32166718
Hepatology. 2002 Jun;35(6):1467-75
pubmed: 12029632
Radiol Med. 2020 Sep;125(9):851-863
pubmed: 32266692
Eur J Surg Oncol. 2013 Jan;39(1):4-16
pubmed: 22980492
Radiol Med. 2021 Mar;126(3):445-452
pubmed: 32812173
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Am J Transl Res. 2017 Feb 15;9(2):580-590
pubmed: 28337285
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Radiol Oncol. 2019 Jan 19;53(1):15-24
pubmed: 30681974
Sci Rep. 2019 Mar 6;9(1):3649
pubmed: 30842517
J Membr Biol. 1972 Dec 29;10(3):279-90
pubmed: 4667921
Spine (Phila Pa 1976). 2015 Dec;40(24):E1340-6
pubmed: 26274530
AJR Am J Roentgenol. 2013 Aug;201(2):246-56
pubmed: 23883206
Eur J Surg Oncol. 2021 Mar 11;:
pubmed: 33726951
Biomed Eng Online. 2015;14 Suppl 3:I1
pubmed: 26355606
Gastroenterol Res Pract. 2016;2016:4508376
pubmed: 26981115
J Bone Joint Surg Br. 2010 Nov;92(11):1614-20
pubmed: 21037363
Radiol Med. 2021 Feb;126(2):323-333
pubmed: 32594427
Radiol Med. 2020 Jun;125(6):522-530
pubmed: 32020526
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Ann Biomed Eng. 2009 Dec;37(12):2615-25
pubmed: 19757056
Diagnostics (Basel). 2017 Feb 15;7(1):
pubmed: 28212290
World J Surg Oncol. 2020 Nov 23;18(1):305
pubmed: 33228665
J Clin Oncol. 2003 Jul 1;21(13):2574-82
pubmed: 12829678
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
AJR Am J Roentgenol. 2002 Jan;178(1):47-51
pubmed: 11756085
World J Gastroenterol. 2017 Jul 14;23(26):4767-4778
pubmed: 28765698
Radiol Med. 2020 Aug;125(8):715-729
pubmed: 32189174
Langenbecks Arch Surg. 2007 Jan;392(1):55-60
pubmed: 17089173
Expert Rev Anticancer Ther. 2010 May;10(5):729-46
pubmed: 20470005
Abdom Radiol (NY). 2018 Oct;43(10):2702-2711
pubmed: 29492602
Medicine (Baltimore). 2015 Mar;94(9):e580
pubmed: 25738477
Indian J Nucl Med. 2015 Apr-Jun;30(2):145-7
pubmed: 25829734
AJR Am J Roentgenol. 2000 Feb;174(2):323-31
pubmed: 10658699
JOP. 2006 Jan 11;7(1):74-8
pubmed: 16407624
Radiol Med. 2014 Jan;119(1):33-40
pubmed: 24234185
Clin Exp Metastasis. 2013 Dec;30(8):1033-45
pubmed: 23832763
Radiol Med. 2019 Jan;124(1):1-7
pubmed: 30132184
Technol Cancer Res Treat. 2007 Aug;6(4):295-300
pubmed: 17668936
Cancer Res. 1995 Aug 1;55(15):3450-5
pubmed: 7614485
Radiol Med. 2019 Jul;124(7):581-587
pubmed: 30806920
Radiol Med. 2019 Dec;124(12):1306-1314
pubmed: 31317380
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):181-192
pubmed: 28490991
J Comput Assist Tomogr. 2013 Mar-Apr;37(2):154-8
pubmed: 23493202
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Radiology. 2005 May;235(2):478-86
pubmed: 15798156
J Surg Oncol. 2014 Sep;110(3):320-7
pubmed: 24782355
Radiol Med. 2019 Jun;124(6):450-459
pubmed: 30712163
Infect Agent Cancer. 2016 Nov 15;11:57
pubmed: 27891175
Front Oncol. 2020 Nov 27;10:560952
pubmed: 33330028
Radiol Med. 2014 Jul;119(7):451-61
pubmed: 24894923
Eur J Surg Oncol. 2020 Sep;46(9):1628-1633
pubmed: 32387070
Radiol Med. 2019 May;124(5):414-421
pubmed: 30560502
World J Gastroenterol. 2017 Feb 7;23(5):906-918
pubmed: 28223736
Radiol Med. 2014 Apr;119(4):215-21
pubmed: 24297581
Radiology. 2011 Feb;258(2):461-8
pubmed: 21131581
Endoscopy. 2016;48 Suppl 1:E144-5
pubmed: 27081874
Biomed Eng Online. 2015;14 Suppl 3:S1
pubmed: 26355703
Radiol Med. 2004 May-Jun;107(5-6):450-8
pubmed: 15195007
AJR Am J Roentgenol. 2009 Feb;192(2):511-4
pubmed: 19155418
Radiol Med. 2019 Sep;124(9):877-886
pubmed: 31172448
Eur J Surg Oncol. 2018 Oct;44(10):1603-1609
pubmed: 30017329
J Med Ultrason (2001). 2017 Jul;44(3):247-254
pubmed: 27933441
Radiographics. 2011 Mar-Apr;31(2):377-90
pubmed: 21415185
Radiographics. 2013 Sep-Oct;33(5):1323-41
pubmed: 24025927
PLoS One. 2017 Jul 7;12(7):e0180709
pubmed: 28686650